CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device; Data was reported at the 46th Annual Conference of the European Society for Artificial Organs (ESAO)
CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover.
Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, delivered an oral presentation, "CorWave LVAD: A physiologic, pulsatile-flow wave membrane pump", as part of the plenary sessions on September 7th.
CorWave previously reported on the successful completion of 30-day follow-up of an earlier in vivo study. The final results of the 60-day experience, presented at the ESAO conference, confirm the CorWave pump's ability to provide chronic circulatory support with outstanding hemocompati...